Acrtoris - Ulysses automated drug discovery platform

Arctoris celebrates 5th anniversary, launches Ulysses robotic platform for drug discovery

Acrtoris - Ulysses automated drug discovery platform

Arctoris, an Oxford-based technology company operating a fully automated drug discovery platform, has – on the occasion of its 5th anniversary – unveiled its new and expanded, next-generation robotic platform, Ulysses.

Arctoris was founded in 2016 as the world’s first fully automated drug discovery platform. Through end-to-end automation, the company’s unique technology platform rapidly delivers reliable, reproducible, and fully auditable datasets enabling better decision-making early in the drug discovery process.

Commenting on the anniversary, the company’s CEO Dr Martin-Immanuel Bittner said: “The drug discovery ecosystem is evolving rapidly, and the key to success is having access to the right data at the right time, to progress the right projects towards the clinic. Arctoris plays an important role in enabling true data-driven drug discovery globally, by generating the data that powers decisions in biotech and pharma companies on three continents.”

Tom Fleming, COO of Arctoris, added: “Drug discovery is undergoing a rapid digital metamorphosis, and Ulysses plays a central catalytic role in that transformation. This success is the result of our amazing team’s dedication and hard work over these past five years, combined with guidance from experienced and insightful advisors and board members. We are looking forward to the next five years, which will see even greater change and accelerated growth, toward a future where treatments and cures can be generated at a fraction of the time and cost, and we are privileged to play our role in building that future.”

Having strengthened its team over the past few years with several high-profile hires and Advisory Board appointments, the company has recently announced partnerships with Insilico Medicine and Syntekabio, while further expanding its operations globally.

The Chairman of the Board, Dr Vishal Gulati, echoed the founders’ enthusiasm: “Five years ago, the founders set out with the idea to make it possible for any scientist in the world to run a biotech company with a laptop and a credit card – and thanks to Arctoris, this is now entirely possible, harnessing the power of automation for drug discovery. As Chairman of the Board of Arctoris, I am incredibly proud of where the Company stands today, and I am excited about what lies ahead, on our path to redesigning drug discovery from the ground up.”